Minerva Neurosciences, Inc. Revenue from Collaborative Arrangement, Excluding Revenue from Contract with Customer
Minerva Neurosciences, Inc. (NERV) reported Revenue from Collaborative Arrangement, Excluding Revenue from Contract with Customer of $41.18 million for the 12-month period ending 2020-12-31, per its 10-K filed 2022-03-01.
Discontinued › Income Statement › Other Income
us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer · last filed 2022-03-01
- Minerva Neurosciences, Inc. revenue from collaborative arrangement, excluding revenue from contract with customer for the quarter ending 2020-12-31 was $0.00.
- Minerva Neurosciences, Inc. revenue from collaborative arrangement, excluding revenue from contract with customer for the quarter ending 2020-09-30 was $0.00.
- Minerva Neurosciences, Inc. revenue from collaborative arrangement, excluding revenue from contract with customer for the quarter ending 2020-06-30 was $41.18M.
- Minerva Neurosciences, Inc. revenue from collaborative arrangement, excluding revenue from contract with customer for fiscal 2020 was $41.18M.
| Period end | Revenue from Collaborative Arrangement, Excluding Revenue from Contract with Customer 3 month | Revenue from Collaborative Arrangement, Excluding Revenue from Contract with Customer 6 month | Revenue from Collaborative Arrangement, Excluding Revenue from Contract with Customer 9 month | Revenue from Collaborative Arrangement, Excluding Revenue from Contract with Customer 12 month |
|---|---|---|---|---|
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $0.00 derived: sum of 2 quarters · filed 2022-03-01 | $41.18M derived: sum of 3 quarters · filed 2022-03-01 | $41.18M 10-K · filed 2022-03-01 |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-08 | $41.18M derived: sum of 2 quarters · filed 2021-11-08 | $41.18M 10-Q · filed 2021-11-08 | |
| 2020-06-30 | $41.18M 10-Q · filed 2021-08-02 | $41.18M 10-Q · filed 2021-08-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 | |
| LIFECORE BIOMEDICAL, INC. DE (LFCR) | United States | $0.163B | -8.50 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |